{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:30:13Z","timestamp":1774294213705,"version":"3.50.1"},"reference-count":312,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The parasellar region is the anatomical area around the sella turcica that represents a crucial crossroad for important adjacent structures. Several distinct tumors can primarily originate from this area, the most common being meningiomas, gliomas, embryonal cell tumors, germ cell tumors, and craniopharyngiomas. In addition, a number of systemic and inflammatory disorders can also affect the parasellar region, most commonly involving the pituitary. These lesions have different pathologic characteristics and malignant potential according to the new World Health Organization CNS5 2021 classification. Signs and symptoms may be nonspecific and are mostly related to a mass effect on the surrounding anatomical structures and\/or impairment of endocrine function, whereas the vast majority lack a secretory component. The mutational signature analysis based on advances in molecular techniques has recently enabled the identification of specific gene mutations or signaling pathway aberrations. These developments may serve as a powerful means to delineate the pathophysiology of these lesions and serve as a diagnostic, prognostic, and therapeutic tool, particularly for high-risk populations. Treatment options include surgery alone or in combination with radiotherapy, chemotherapy, and disease-specific medical therapy, in order to prevent recurrence or further tumor growth along with replacement of coexistent pituitary hormonal deficiencies. In this comprehensive review, we present the current state-of-the-art developments in the histopathology and molecular biology of parasellar lesions, which often represent a diagnostic and therapeutic challenge, that may be utilized by a dedicated multidisciplinary team for the diagnosis, monitoring, and treatment of these lesions.<\/jats:p>","DOI":"10.1210\/endrev\/bnae020","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:56:10Z","timestamp":1722041770000},"page":"880-911","source":"Crossref","is-referenced-by-count":1,"title":["Molecular Developments in Parasellar Tumors and Potential Therapeutic Implications"],"prefix":"10.1210","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-747X","authenticated-orcid":false,"given":"Paraskevi","family":"Xekouki","sequence":"first","affiliation":[{"name":"Endocrinology & Diabetes Clinic, University Hospital of Heraklion, University of Crete, School of Medicine , Crete, 71500 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Venetsanaki","sequence":"additional","affiliation":[{"name":"Endocrinology & Diabetes Clinic, University Hospital of Heraklion, University of Crete, School of Medicine , Crete, 71500 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Pathology Department, Evangelismos General Hospital , Athens, 10676 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystallenia","family":"Alexandraki","sequence":"additional","affiliation":[{"name":"2nd Department of Surgery, Aretaieio Athens Hospital, Medical School, National and Kapodistrian University of Athens , Athens, 11528 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-3617","authenticated-orcid":false,"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[{"name":"1st Department of Internal Medicine, Laikon University Hospital, National and Kapodistrian University of Athens , Athens, 11527 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7883","authenticated-orcid":false,"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[{"name":"1st Department of Propaedeutic Internal Medicine, Laikon University Hospital, National and Kapodistrian University of Athens , Athens, 11527 ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"8","key":"2024112123521443700_bnae020-B1","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1210\/jc.2018-01871","article-title":"Nonneuroendocrine neoplasms of the pituitary region","volume":"104","author":"Kaltsas","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024112123521443700_bnae020-B2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2024112123521443700_bnae020-B3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"Suppl\\ 5","key":"2024112123521443700_bnae020-B4","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"8","key":"2024112123521443700_bnae020-B5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/annonc\/mdz164","article-title":"Molecular pathology of tumors of the central nervous system","volume":"30","author":"Kristensen","year":"2019","journal-title":"Ann Oncol"},{"key":"2024112123521443700_bnae020-B6","first-page":"2","volume-title":"Central Nervous System Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2021","edition":"5th edition"},{"issue":"2","key":"2024112123521443700_bnae020-B7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41374-021-00667-6","article-title":"Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System","volume":"102","author":"Komori","year":"2022","journal-title":"Lab Invest"},{"issue":"2","key":"2024112123521443700_bnae020-B8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/cns.12.47","article-title":"Optic pathway gliomas: a review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol"},{"issue":"1","key":"2024112123521443700_bnae020-B9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0040-1722634","article-title":"Optic nerve gliomas","volume":"82","author":"Wladis","year":"2021","journal-title":"J Neurol Surg B Skull Base"},{"key":"2024112123521443700_bnae020-B10","volume-title":"Optic Nerve Glioma","author":"Huang","year":"2024"},{"issue":"1","key":"2024112123521443700_bnae020-B11","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"2024112123521443700_bnae020-B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-030-38490-6_1","volume-title":"Diseases of the Brain, Head and Neck, Spine 2020\u20132023: Diagnostic Imaging","author":"Kucharczyk","year":"2020"},{"key":"2024112123521443700_bnae020-B13","unstructured":"Xekouki P, Venetsanaki V, et al \u00a0Supplemental Tables Molecular developments in parasellar tumors and potential therapeutic implications.odt. Doi:10.6084\/M9.FIGSHARE.25231730"},{"issue":"4","key":"2024112123521443700_bnae020-B14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.2000-0312","article-title":"Intracranial germ cell tumors; intracranial germ cell tumors","volume":"5","author":"Packer","year":"2000","journal-title":"Oncologist"},{"issue":"8","key":"2024112123521443700_bnae020-B15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MPH.0b013e3181983af5","article-title":"Incidence patterns of central nervous system germ cell tumors: a SEER study","volume":"31","author":"Goodwin","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"2024112123521443700_bnae020-B16","first-page":"1719","article-title":"Primary central nervous system germ cell tumors: a review and update","volume":"6","author":"Fetcko","year":"2018","journal-title":"Med Res Arch"},{"issue":"1","key":"2024112123521443700_bnae020-B17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0090-3019(96)00152-8","article-title":"Intracranial germinoma with Down's syndrome: a case report and review of the literature","volume":"47","author":"Tanabe","year":"1997","journal-title":"Surg Neurol"},{"issue":"4","key":"2024112123521443700_bnae020-B18","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.humpath.2006.01.029","article-title":"Extragonadal germ cell tumors are often associated with Klinefelter syndrome","volume":"37","author":"Aguirre","year":"2006","journal-title":"Hum Pathol"},{"issue":"5","key":"2024112123521443700_bnae020-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10051054","article-title":"Chordoma\u2014current understanding and modern treatment paradigms","volume":"10","author":"Barber","year":"2021","journal-title":"J Clin Med"},{"key":"2024112123521443700_bnae020-B20","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1016\/j.wneu.2017.10.054","article-title":"Presentation, treatment, and long-term outcome of intrasellar chordoma: a pooled analysis of institutional, SEER (surveillance epidemiology and End results), and published data","volume":"109","author":"Ahmed","year":"2018","journal-title":"World Neurosurg"},{"issue":"3","key":"2024112123521443700_bnae020-B21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5858\/arpa.2020-0258-RA","article-title":"Chordomaa review and differential diagnosis","volume":"146","author":"Ulici","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2024112123521443700_bnae020-B22","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","article-title":"Chordoma: current concepts, management, and future directions","volume":"13","author":"Walcott","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9-10","key":"2024112123521443700_bnae020-B23","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1159\/000509386","article-title":"Skull base chordomas and chondrosarcomas","volume":"110","author":"Kremenevski","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"12","key":"2024112123521443700_bnae020-B24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jocn.2009.05.003","article-title":"A systematic review of intracranial chondrosarcoma and survival","volume":"16","author":"Bloch","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"9","key":"2024112123521443700_bnae020-B25","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know\u2014a minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"2024112123521443700_bnae020-B26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00401-014-1285-z","article-title":"Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations","volume":"128","author":"De Kock","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2024112123521443700_bnae020-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-005-3328-x","article-title":"Sellar neuroblastoma mimicking pituitary adenoma","volume":"8","author":"Oyama","year":"2005","journal-title":"Pituitary"},{"issue":"4","key":"2024112123521443700_bnae020-B28","doi-asserted-by":"crossref","first-page":"luad081","DOI":"10.1210\/jcemcr\/luad081","article-title":"Primary sellar neuroblastoma masquerading as a pituitary macroadenoma","volume":"1","author":"Seshan","year":"2023","journal-title":"JCEM Case Reports"},{"issue":"6","key":"2024112123521443700_bnae020-B29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2024112123521443700_bnae020-B30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2024112123521443700_bnae020-B31","doi-asserted-by":"crossref","first-page":"1090615","DOI":"10.3389\/fonc.2023.1090615","article-title":"Case report: paraganglioma in the sellar region: longitudinal observation and surgical outcome","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"2024112123521443700_bnae020-B32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1227\/00006123-199305000-00021","article-title":"Paragangliomas of the sellar region: report of two cases","volume":"32","author":"Steel","year":"1993","journal-title":"Neurosurgery"},{"issue":"5","key":"2024112123521443700_bnae020-B33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/02688697.2021.1902477","article-title":"Primary and metastatic paraganglioma of the cranial vault","volume":"37","author":"Kakodkar","year":"2023","journal-title":"Br J Neurosurg"},{"issue":"2","key":"2024112123521443700_bnae020-B34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma andparaganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"2024112123521443700_bnae020-B35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00441-018-2791-4","article-title":"Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma","volume":"372","author":"Ta\u00efeb","year":"2018","journal-title":"Cell Tissue Res"},{"key":"2024112123521443700_bnae020-B36","first-page":"69","volume-title":"A Case of Sellar Paraganlioma; Rarest of the Rare","author":"Khan","year":"2020"},{"issue":"3","key":"2024112123521443700_bnae020-B37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"2024112123521443700_bnae020-B38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.4158\/EP-2020-0286","article-title":"Primary pituitary lymphoma as rare cause of a pituitary mass and hypopituitarism in adulthood","volume":"26","author":"Caputo","year":"2020","journal-title":"Endocr Pract"},{"key":"2024112123521443700_bnae020-B39","doi-asserted-by":"crossref","first-page":"562850","DOI":"10.3389\/fendo.2020.562850","article-title":"Primary pituitary lymphoma in immunocompetent patients: a report on two case studies and the review of literature","volume":"11","author":"Duan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2024112123521443700_bnae020-B40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and etiology of meningioma","volume":"99","author":"Wiemels","year":"2010","journal-title":"J Neurooncol"},{"issue":"9-10","key":"2024112123521443700_bnae020-B41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000509090","article-title":"Parasellar meningiomas","volume":"110","author":"Graillon","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2024112123521443700_bnae020-B42","first-page":"253","volume-title":"Handbook of Clinical Neurology","author":"Phillips","year":"2020"},{"key":"2024112123521443700_bnae020-B43","first-page":"321","volume-title":"StatPearls","author":"Alruwaili","year":"2023"},{"issue":"3","key":"2024112123521443700_bnae020-B44","first-page":"319","article-title":"Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions","volume":"9","author":"Ogasawara","year":"2021","journal-title":"Biomed"},{"issue":"1","key":"2024112123521443700_bnae020-B45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0033-8389(05)70081-6","article-title":"Imaging of sellar and parasellar pathology","volume":"37","author":"FitzPatrick","year":"1999","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"2024112123521443700_bnae020-B46","first-page":"1","article-title":"Craniopharyngioma","volume":"5","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"2024112123521443700_bnae020-B47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrendo.2016.217","article-title":"New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma","volume":"13","author":"M\u00fcller","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2024112123521443700_bnae020-B48","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/endrev\/bnac035","article-title":"Contemporary biological insights and clinical management of craniopharyngioma","volume":"44","author":"Apps","year":"2023","journal-title":"Endocr Rev"},{"key":"2024112123521443700_bnae020-B49","first-page":"1","volume-title":"Adult Craniopharyngiomas Differ Lessons from Paediatr","author":"Vasiljevic","year":"2020"},{"issue":"22","key":"2024112123521443700_bnae020-B50","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2024112123521443700_bnae020-B51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/neuonc\/noab107","article-title":"Histiocytosis and the nervous system: from diagnosis to targeted therapies","volume":"23","author":"Cohen Aubart","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2265.2011.04235.x","article-title":"Rathke's cleft cysts","volume":"76","author":"Trifanescu","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024112123521443700_bnae020-B53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cen.14622","article-title":"Natural history and surgical outcome of Rathke's cleft cysts-A study from the Swedish Pituitary Registry","volume":"96","author":"Petersson","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2024112123521443700_bnae020-B54","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.3171\/2011.5.FOCUS1178","article-title":"Rathke cleft cysts in pediatric patients: presentation, surgical management, and postoperative outcomes","volume":"31","author":"Jahangiri","year":"2011","journal-title":"Neurosurg Focus"},{"issue":"3","key":"2024112123521443700_bnae020-B55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bpa.12125","article-title":"Schwannomas and their pathogenesis","volume":"24","author":"Hilton","year":"2014","journal-title":"Brain Pathol"},{"key":"2024112123521443700_bnae020-B56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.25259\/SNI_658_2022","article-title":"Ectopic schwannoma of the sellar region in a 1-year-old child: a case report and review of literature","volume":"13","author":"Sadiqo","year":"2022","journal-title":"Surg Neurol Int"},{"issue":"6","key":"2024112123521443700_bnae020-B57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ons\/opx174","article-title":"Parasellar schwannomas: extradural vs extra-intradural surgical approach","volume":"14","author":"Mariniello","year":"2018","journal-title":"Oper Neurosurg"},{"issue":"5","key":"2024112123521443700_bnae020-B58","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/02688690500390391","article-title":"Primary intrasellar schwannoma: clinical, aetiopathological and surgical considerations","volume":"19","author":"Honegger","year":"2005","journal-title":"Br J Neurosurg"},{"issue":"4","key":"2024112123521443700_bnae020-B59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2024112123521443700_bnae020-B60","doi-asserted-by":"crossref","first-page":"106076","DOI":"10.1016\/j.clineuro.2020.106076","article-title":"Hypothalamic hamartomas: a comprehensive review of the literature\u2014part 1: Neurobiological features, clinical presentations and advancements in diagnostic tools","volume":"197","author":"Alomari","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"2024112123521443700_bnae020-B61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ajmg.1320070110","article-title":"Congenital hypothalamic hamartoblastoma, hypopituitarism, imperforate anus and postaxial polydactyly--a new syndrome? Part I: clinical, causal, and pathogenetic considerations","volume":"7","author":"Hall","year":"1980","journal-title":"Am J Med Genet"},{"issue":"18","key":"2024112123521443700_bnae020-B62","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.0000000000012773","article-title":"Hypothalamic hamartomas: evolving understanding and management","volume":"97","author":"Cohen","year":"2021","journal-title":"Neurology"},{"issue":"9-10","key":"2024112123521443700_bnae020-B63","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1159\/000506903","article-title":"Hypophysitis (including IgG4 and immunotherapy)","volume":"110","author":"Angelousi","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2024112123521443700_bnae020-B64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000480086","article-title":"New molecular, biological, and immunological agents inducing hypophysitis","volume":"106","author":"Angelousi","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2024112123521443700_bnae020-B65","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.3390\/ijms24065917","article-title":"Hypophysitis: defining histopathologic variants and a review of emerging clinical causative entities","volume":"24","author":"Rawanduzy","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2024112123521443700_bnae020-B66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/clinem\/dgab672","article-title":"Hypophysitis, the growing Spectrum of a rare pituitary disease","volume":"107","author":"Langlois","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024112123521443700_bnae020-B67","first-page":"3455","article-title":"Unusual causes of sellar\/parasellar masses in a large transsphenoidal surgical series","volume":"81","author":"Freda","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024112123521443700_bnae020-B68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","article-title":"Hypothalamic syndrome","volume":"8","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"2024112123521443700_bnae020-B69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-11-0158","article-title":"Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up","volume":"165","author":"M\u00fcller","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2024112123521443700_bnae020-B70","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/dom.14366","article-title":"MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity","volume":"23","author":"Perez","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024112123521443700_bnae020-B71","doi-asserted-by":"crossref","first-page":"551493","DOI":"10.3389\/fendo.2021.551493","article-title":"Case report: sellar ependymomas: a clinic-pathological study and literature review","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024112123521443700_bnae020-B72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-3-319-22855-6_37","volume-title":"Atlas of Sellar and Parasellar Lesions.","author":"Zada","year":"2016"},{"issue":"3","key":"2024112123521443700_bnae020-B73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00304332","article-title":"Germ cell tumor in the hypothalamo-neurohypophysial region: clinical features and treatment","volume":"16","author":"Nishio","year":"1993","journal-title":"Neurosurg Rev"},{"issue":"9","key":"2024112123521443700_bnae020-B74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0883073818772470","article-title":"Central nervous system germ cell tumors: a review of the literature","volume":"33","author":"Kong","year":"2018","journal-title":"J Child Neurol"},{"issue":"3","key":"2024112123521443700_bnae020-B75","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/neuros\/nyaa108","article-title":"Novel diagnostic methods and posttreatment clinical phenotypes among intracranial germ cell tumors","volume":"87","author":"Takami","year":"2020","journal-title":"Neurosurgery"},{"issue":"11","key":"2024112123521443700_bnae020-B76","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1210\/jc.2014-1680","article-title":"Diencephalic syndrome in childhood craniopharyngioma\u2014results of German multicenter studies on 485 long-term survivors of childhood craniopharyngioma","volume":"99","author":"Hoffmann","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2024112123521443700_bnae020-B77","doi-asserted-by":"crossref","first-page":"e1245","DOI":"10.1016\/j.wneu.2018.09.053","article-title":"Craniopharyngiomas primarily involving the hypothalamus: a model of neurosurgical lesions to elucidate the neurobiological basis of psychiatric disorders","volume":"120","author":"Pascual","year":"2018","journal-title":"World Neurosurg"},{"issue":"2","key":"2024112123521443700_bnae020-B78","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3171\/2016.11.JNS162082","article-title":"Clival chordomas: considerations after 16 years of endoscopic endonasal surgery","volume":"128","author":"Zoli","year":"2018","journal-title":"J Neurosurg"},{"issue":"11","key":"2024112123521443700_bnae020-B79","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/humu.23877","article-title":"Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes","volume":"40","author":"de Kock","year":"2019","journal-title":"Hum Mutat"},{"issue":"2","key":"2024112123521443700_bnae020-B80","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/clinem\/dgaa857","article-title":"Clinical outcomes and complications of pituitary blastoma","volume":"106","author":"Liu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024112123521443700_bnae020-B81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/ajcp\/aqy155","article-title":"Two extraordinary sellar neuronal TumorsLiterature review and comparison of clinicopathologic features","volume":"151","author":"Tan","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2024112123521443700_bnae020-B82","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.20425","article-title":"Risk factors for diabetes insipidus in langerhans cell histiocytosis","volume":"46","author":"Crois","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2024112123521443700_bnae020-B83","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tem.2007.06.003","article-title":"Endocrine manifestations in langerhans cell histiocytosis","volume":"18","author":"Makras","year":"2007","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2024112123521443700_bnae020-B84","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1210\/jcem.85.4.6501","article-title":"Hypothalamo-Pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment","volume":"85","author":"Kaltsas","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"2024112123521443700_bnae020-B85","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.2021014343","article-title":"International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults","volume":"139","author":"Goyal","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024112123521443700_bnae020-B86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.26784","article-title":"Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas","volume":"65","author":"Yeh","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2024112123521443700_bnae020-B87","first-page":"1470","article-title":"Pituitary lymphoma presenting as fever of unknown origin","volume":"86","author":"Landman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024112123521443700_bnae020-B88","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2007.08.021","article-title":"Sellar lymphoma mimicking sphenoid infection presenting with cavernous sinus syndrome","volume":"15","author":"Chen","year":"2008","journal-title":"J Clin Neurosci"},{"issue":"3","key":"2024112123521443700_bnae020-B89","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11060-016-2249-z","article-title":"Primary pituitary lymphoma: an update of the literature","volume":"130","author":"Tarabay","year":"2016","journal-title":"J Neurooncol"},{"issue":"3","key":"2024112123521443700_bnae020-B90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2176\/nmccrj.cr.2016-0267","article-title":"\u201cPure\u201d suprasellar schwannoma presented with communicating hydrocephalus: a case report","volume":"4","author":"Oishi","year":"2017","journal-title":"NMC Case Rep J"},{"issue":"3","key":"2024112123521443700_bnae020-B91","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/neuros\/nyab019","article-title":"Pathological features of tumors of the nervous system in hereditary cancer predisposition syndromes: a review","volume":"89","author":"Tadros","year":"2021","journal-title":"Neurosurgery"},{"issue":"1","key":"2024112123521443700_bnae020-B92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.yebeh.2012.02.013","article-title":"The gelastic seizures-hypothalamic hamartoma syndrome: facts, hypotheses, and perspectives","volume":"24","author":"Striano","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"1","key":"2024112123521443700_bnae020-B93","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.0013-9580.2005.68303.x","article-title":"Hypothalamic hamartomas and seizures: distinct natural history of isolated and pallister-Hall syndrome cases","volume":"46","author":"Boudreau","year":"2005","journal-title":"Epilepsia"},{"issue":"2","key":"2024112123521443700_bnae020-B94","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11060-013-1272-6","article-title":"Rathke's cleft cysts: review of natural history and surgical outcomes","volume":"117","author":"Han","year":"2014","journal-title":"J Neurooncol"},{"issue":"2","key":"2024112123521443700_bnae020-B95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3171\/jns.2005.102.2.0189","article-title":"Surgical outcomes in 118 patients with Rathke cleft cysts","volume":"102","author":"Aho","year":"2005","journal-title":"J Neurosurg"},{"issue":"10","key":"2024112123521443700_bnae020-B96","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2015-2604","article-title":"A case for conservative management: characterizing the natural history of radiographically diagnosed rathke cleft cysts","volume":"100","author":"Culver","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024112123521443700_bnae020-B97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"2024112123521443700_bnae020-B98","author":"Menotti"},{"issue":"1","key":"2024112123521443700_bnae020-B99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13578-017-0165-3","article-title":"Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight","volume":"7","author":"Al-Khallaf","year":"2017","journal-title":"Cell Biosci"},{"issue":"1","key":"2024112123521443700_bnae020-B100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-022-01323-w","article-title":"Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology","volume":"10","author":"Mehani","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"2024112123521443700_bnae020-B101","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2024112123521443700_bnae020-B102","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-Hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat Med"},{"issue":"10","key":"2024112123521443700_bnae020-B103","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2024112123521443700_bnae020-B104","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024112123521443700_bnae020-B105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024112123521443700_bnae020-B106","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"issue":"9","key":"2024112123521443700_bnae020-B107","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1074\/jbc.M112.411603","article-title":"Alpha thalassemia\/mental retardation syndrome X-linked gene product ATRX is required for proper replication restart and cellular resistance to replication stress","volume":"288","author":"Leung","year":"2013","journal-title":"J Biol Chem"},{"issue":"5","key":"2024112123521443700_bnae020-B108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00401-012-1031-3","article-title":"Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1\/IDH2 and TP53 mutations","volume":"124","author":"Liu","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"10","key":"2024112123521443700_bnae020-B109","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.18632\/oncotarget.689","article-title":"Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma","volume":"3","author":"Kannan","year":"2012","journal-title":"Oncotarget"},{"issue":"26","key":"2024112123521443700_bnae020-B110","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","article-title":"Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas","volume":"372","author":"Brat","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2024112123521443700_bnae020-B111","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"issue":"2","key":"2024112123521443700_bnae020-B112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11060-020-03528-2","article-title":"The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature","volume":"148","author":"Lu","year":"2020","journal-title":"J Neurooncol"},{"issue":"7","key":"2024112123521443700_bnae020-B113","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor-tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"6","key":"2024112123521443700_bnae020-B114","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jocn.2008.12.005","article-title":"The EGFRvIII variant in glioblastoma multiforme","volume":"16","author":"Gan","year":"2009","journal-title":"J Clin Neurosci"},{"issue":"19","key":"2024112123521443700_bnae020-B115","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2013.198","article-title":"EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180","volume":"33","author":"Feng","year":"2014","journal-title":"Oncogene"},{"issue":"21","key":"2024112123521443700_bnae020-B116","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"issue":"9","key":"2024112123521443700_bnae020-B117","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/cancers11091262","article-title":"BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors","volume":"11","author":"Schreck","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024112123521443700_bnae020-B118","first-page":"1","article-title":"Understanding inherited genetic risk of adult glioma\u2014a review","volume":"3","author":"Rice","year":"2016","journal-title":"Neuro-Oncology Pract"},{"issue":"1","key":"2024112123521443700_bnae020-B119","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S1470-2045(14)71178-7","article-title":"POT1: a genetic link for familial glioma","volume":"16","author":"Bagcchi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024112123521443700_bnae020-B120","doi-asserted-by":"crossref","first-page":"561487","DOI":"10.3389\/fped.2020.561487","article-title":"Cancer predisposition syndromes associated with pediatric high-grade gliomas","volume":"8","author":"Ceglie","year":"2020","journal-title":"Front Pediatr"},{"issue":"34","key":"2024112123521443700_bnae020-B121","doi-asserted-by":"crossref","first-page":"55026","DOI":"10.18632\/oncotarget.10392","article-title":"CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras\/Raf\/Erk- and Akt-pathways","volume":"7","author":"Schulte","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2024112123521443700_bnae020-B122","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00401-014-1247-5","article-title":"Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas","volume":"127","author":"Fukushima","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"7508","key":"2024112123521443700_bnae020-B123","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature13296","article-title":"Novel somatic and germline mutations in intracranial germ cell tumours","volume":"511","author":"Wang","year":"2014","journal-title":"Nature"},{"issue":"6","key":"2024112123521443700_bnae020-B124","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00401-016-1557-x","article-title":"Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy","volume":"131","author":"Ichimura","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"7287","key":"2024112123521443700_bnae020-B125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"issue":"12","key":"2024112123521443700_bnae020-B126","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/neuonc\/noz139","article-title":"Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT consortium","volume":"21","author":"Takami","year":"2019","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024112123521443700_bnae020-B127","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2011.5.JNS11185","article-title":"Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target","volume":"115","author":"Hsu","year":"2011","journal-title":"J Neurosurg"},{"issue":"2","key":"2024112123521443700_bnae020-B128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10014-017-0283-y","article-title":"Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma","volume":"34","author":"Kitamura","year":"2017","journal-title":"Brain Tumor Pathol"},{"issue":"7","key":"2024112123521443700_bnae020-B129","doi-asserted-by":"crossref","first-page":"e101283","DOI":"10.1371\/journal.pone.0101283","article-title":"Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1","volume":"9","author":"Choy","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"2024112123521443700_bnae020-B130","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/carcin\/bgu014","article-title":"The FGFR\/MEK\/ERK\/brachyury pathway is critical for chordoma cell growth and survival","volume":"35","author":"Hu","year":"2014","journal-title":"Carcinogenesis"},{"issue":"2","key":"2024112123521443700_bnae020-B131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-014-1445-y","article-title":"MGMT promoter methylation status in clival chordoma","volume":"118","author":"Marucci","year":"2014","journal-title":"J Neurooncol"},{"issue":"4","key":"2024112123521443700_bnae020-B132","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12178-015-9311-x","article-title":"Chordoma: an update on the pathophysiology and molecular mechanisms","volume":"8","author":"Sun","year":"2015","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"3","key":"2024112123521443700_bnae020-B133","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"issue":"14","key":"2024112123521443700_bnae020-B134","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024112123521443700_bnae020-B135","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/00000478-200112000-00008","article-title":"Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome","volume":"25","author":"Sulzbacher","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2024112123521443700_bnae020-B136","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/CS20140390","article-title":"Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis","volume":"129","author":"Tzeng","year":"2015","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"2024112123521443700_bnae020-B137","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.MP.0000043522.76788.0A","article-title":"Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma","volume":"16","author":"Sulzbacher","year":"2003","journal-title":"Mod Pathol"},{"issue":"9a","key":"2024112123521443700_bnae020-B138","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1582-4934.2008.00406.x","article-title":"Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro","volume":"13","author":"Schrage","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"8","key":"2024112123521443700_bnae020-B139","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"2024112123521443700_bnae020-B140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3171\/2014.12.JNS142059","article-title":"Genetic characterization of skull base chondrosarcomas","volume":"123","author":"Kanamori","year":"2015","journal-title":"J Neurosurg"},{"issue":"5","key":"2024112123521443700_bnae020-B141","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3171\/jns.1996.85.5.0953","article-title":"Differentiating neuroblastoma of pituitary gland: neuroblastic transformation of epithelial adenoma cells. Case report","volume":"85","author":"Lach","year":"1996","journal-title":"J Neurosurg"},{"issue":"04","key":"2024112123521443700_bnae020-B142","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.4103\/ajns.AJNS_30_17","article-title":"Sellar embryonal tumor: a case report and review of the literature","volume":"13","author":"Yakar","year":"2018","journal-title":"Asian J Neurosurg"},{"issue":"3","key":"2024112123521443700_bnae020-B143","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3171\/2022.6.PEDS22119","article-title":"A systematic review of the clinicopathological features and prognostic outcomes of DICER1-mutant malignant brain neoplasms","volume":"30","author":"Vuong","year":"2022","journal-title":"J Neurosurg Pediatr"},{"issue":"6818","key":"2024112123521443700_bnae020-B144","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"issue":"5943","key":"2024112123521443700_bnae020-B145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.1174334","article-title":"DICER1 mutations in familial pleuropulmonary blastoma","volume":"325","author":"Hill","year":"2009","journal-title":"Science"},{"issue":"8","key":"2024112123521443700_bnae020-B146","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2018.78.4678","article-title":"Neoplasm risk among individuals with a pathogenic germline variant in DICER1","volume":"37","author":"Stewart","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024112123521443700_bnae020-B147","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10689-021-00264-y","article-title":"Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE host genome working group and CanGene-CanVar clinical guideline working group","volume":"20","author":"Bakhuizen","year":"2021","journal-title":"Fam Cancer"},{"issue":"8","key":"2024112123521443700_bnae020-B148","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"issue":"6","key":"2024112123521443700_bnae020-B149","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lio2.122","article-title":"Head and neck paragangliomas: a two-decade institutional experience and algorithm for management","volume":"2","author":"Smith","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"9","key":"2024112123521443700_bnae020-B150","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1200\/JCO.2005.07.198","article-title":"Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD","volume":"23","author":"Dannenberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"SUPPLEMENT","key":"2024112123521443700_bnae020-B151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6061\/clinics\/2012(Sup01)05","article-title":"Head and neck paragangliomas: clinical and molecular genetic classification","volume":"67","author":"Offergeld","year":"2012","journal-title":"Clinics"},{"issue":"6","key":"2024112123521443700_bnae020-B152","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"2024112123521443700_bnae020-B153","doi-asserted-by":"crossref","first-page":"e220167","DOI":"10.1530\/JME-22-0167","article-title":"Genetic bases of pheochromocytoma and paraganglioma","volume":"70","author":"Casc\u00f3n","year":"2023","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"2024112123521443700_bnae020-B154","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.1210\/jc.2011-1179","article-title":"Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?","volume":"97","author":"Xekouki","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"07","key":"2024112123521443700_bnae020-B155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/a-0661-0341","article-title":"The 3PAs: an update on the association of pheochromocytomas, paragangliomas, and pituitary tumors","volume":"51","author":"Xekouki","year":"2019","journal-title":"Horm Metab Res"},{"issue":"1","key":"2024112123521443700_bnae020-B156","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"key":"2024112123521443700_bnae020-B157","doi-asserted-by":"crossref","first-page":"739255","DOI":"10.3389\/fonc.2021.739255","article-title":"Case report: malignant primary sellar paraganglioma with unusual genetic and imaging features","volume":"11","author":"Stojanoski","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"2024112123521443700_bnae020-B158","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024112123521443700_bnae020-B159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"2","key":"2024112123521443700_bnae020-B160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"issue":"6","key":"2024112123521443700_bnae020-B161","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","article-title":"Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival","volume":"11","author":"Stamenkovic","year":"2010","journal-title":"Curr Protein Pept Sci"},{"issue":"5","key":"2024112123521443700_bnae020-B162","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"2024112123521443700_bnae020-B163","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/gcc.2870100207","article-title":"Deletions on chromosome 22 in sporadic meningioma","volume":"10","author":"Ruttledge","year":"1994","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"2024112123521443700_bnae020-B164","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1073\/pnas.94.26.14719","article-title":"Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression","volume":"94","author":"Weber","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024112123521443700_bnae020-B165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","article-title":"Molecular characteristics of meningiomas","volume":"54","author":"Lee","year":"2020","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"2024112123521443700_bnae020-B166","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-022-04228-9","article-title":"Molecular classification and grading of meningioma","volume":"161","author":"Nasrallah","year":"2023","journal-title":"J Neurooncol"},{"issue":"6123","key":"2024112123521443700_bnae020-B167","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"issue":"18","key":"2024112123521443700_bnae020-B168","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.3390\/cancers15184521","article-title":"Novel advances in treatment of meningiomas: prognostic and therapeutic implications","volume":"15","author":"Caruso","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"65","key":"2024112123521443700_bnae020-B169","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"2024112123521443700_bnae020-B170","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2024112123521443700_bnae020-B171","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2021.06.005","article-title":"The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma","volume":"115","author":"Jung","year":"2021","journal-title":"Hum Pathol"},{"issue":"2","key":"2024112123521443700_bnae020-B172","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-023-04253-2","article-title":"The multiomic landscape of meningiomas: a review and update","volume":"161","author":"Wang","year":"2023","journal-title":"J Neurooncol"},{"issue":"3","key":"2024112123521443700_bnae020-B173","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"5","key":"2024112123521443700_bnae020-B174","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2024112123521443700_bnae020-B175","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024112123521443700_bnae020-B176","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"2024112123521443700_bnae020-B177","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3389\/fimmu.2019.02872","article-title":"Wnt signaling and its significance within the tumor microenvironment: novel therapeutic insights","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"2024112123521443700_bnae020-B178","first-page":"1","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2024112123521443700_bnae020-B179","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","article-title":"Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond \u03b2-catenin and the destruction complex","volume":"52","author":"Jung","year":"2020","journal-title":"Exp Mol Med"},{"issue":"28","key":"2024112123521443700_bnae020-B180","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.1101553108","article-title":"Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans","volume":"108","author":"Gaston-Massuet","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2024112123521443700_bnae020-B181","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.stem.2013.07.004","article-title":"Sox2+ stem\/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential","volume":"13","author":"Andoniadou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2024112123521443700_bnae020-B182","first-page":"1","article-title":"Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma","volume":"8","author":"Mario Gonzalez-Meljem","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"2024112123521443700_bnae020-B183","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2024112123521443700_bnae020-B184","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/2016.9.FOCUS16316","article-title":"Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin","volume":"41","author":"Stache","year":"2016","journal-title":"Neurosurg Focus"},{"issue":"4","key":"2024112123521443700_bnae020-B185","doi-asserted-by":"crossref","first-page":"136","DOI":"10.31083\/j.fbl2704136","article-title":"Targeted therapy in the management of modern craniopharyngiomas","volume":"27","author":"Reyes","year":"2022","journal-title":"Front Biosci"},{"issue":"12","key":"2024112123521443700_bnae020-B186","first-page":"2141","article-title":"MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma","volume":"144","author":"Haston","year":"2017","journal-title":"Development"},{"issue":"11","key":"2024112123521443700_bnae020-B187","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian-Very","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2024112123521443700_bnae020-B188","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","article-title":"Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis","volume":"124","author":"Chakraborty","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2024112123521443700_bnae020-B189","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2016-12-757823","article-title":"Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults","volume":"130","author":"Milne","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2024112123521443700_bnae020-B190","first-page":"4501","article-title":"Rathke's cleft-like cysts arise from isl1 deletion in murine pituitary progenitors","volume":"130","author":"Brinkmeier","year":"2020","journal-title":"J Clin Invest"},{"key":"2024112123521443700_bnae020-B191","doi-asserted-by":"crossref","first-page":"e43996","DOI":"10.7554\/eLife.43996","article-title":"Homeostatic and tumourigenic activity of SOX2 +pituitary stem cells is controlled by the LATS\/YAP\/TAZ cascade","volume":"8","author":"Lodge","year":"2019","journal-title":"Elife"},{"issue":"6","key":"2024112123521443700_bnae020-B192","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/nan.12201","article-title":"BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts","volume":"41","author":"Schweizer","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"2024112123521443700_bnae020-B193","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41436-018-0384-y","article-title":"Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing","volume":"21","author":"Evans","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"2024112123521443700_bnae020-B194","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/513207","article-title":"Germline mutation of INI1\/SMARCB1 in familial schwannomatosis","volume":"80","author":"Hulsebos","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2024112123521443700_bnae020-B195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/humu.20679","article-title":"Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas","volume":"29","author":"Sestini","year":"2008","journal-title":"Hum Mutat"},{"issue":"4","key":"2024112123521443700_bnae020-B196","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1399-0004.2008.01060.x","article-title":"Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis","volume":"74","author":"Boyd","year":"2008","journal-title":"Clin Genet"},{"issue":"3","key":"2024112123521443700_bnae020-B197","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: from genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2024112123521443700_bnae020-B198","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat Genet"},{"issue":"3","key":"2024112123521443700_bnae020-B199","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajmg.a.36312","article-title":"CTF meeting 2012: translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies","volume":"0","author":"Widemann","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2024112123521443700_bnae020-B200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00439-016-1753-8","article-title":"The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis","volume":"136","author":"Kehrer-Sawatzki","year":"2017","journal-title":"Hum Genet"},{"issue":"21","key":"2024112123521443700_bnae020-B201","doi-asserted-by":"crossref","first-page":"dev167379","DOI":"10.1242\/dev.167379","article-title":"Distinct temporal requirements for sonic hedgehog signaling in development of the tuberal hypothalamus","volume":"145","author":"Corman","year":"2018","journal-title":"Development"},{"issue":"2","key":"2024112123521443700_bnae020-B202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajhg.2016.05.031","article-title":"Mutations of the sonic hedgehog pathway underlie hypothalamic hamartoma with gelastic epilepsy","volume":"99","author":"Hildebrand","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2024112123521443700_bnae020-B203","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ng0397-266","article-title":"GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome","volume":"15","author":"Kang","year":"1997","journal-title":"Nat Genet"},{"issue":"6","key":"2024112123521443700_bnae020-B204","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1073\/pnas.96.6.2880","article-title":"GLI3 mutations in human disorders mimic Drosophila cubitus interruptus protein functions and localization","volume":"96","author":"Shin","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024112123521443700_bnae020-B205","doi-asserted-by":"crossref","first-page":"106261","DOI":"10.1016\/j.nbd.2023.106261","article-title":"Brain mosaicism of hedgehog signalling and other cilia genes in hypothalamic hamartoma","volume":"185","author":"Green","year":"2023","journal-title":"Neurobiol Dis"},{"issue":"11","key":"2024112123521443700_bnae020-B206","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jc.2015-2702","article-title":"HLA markers DQ8 and DR53 are associated with lymphocytic hypophysitis and may aid in differential diagnosis","volume":"100","author":"Heaney","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024112123521443700_bnae020-B207","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1423-0127-19-88","article-title":"HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing","volume":"19","author":"Megiorni","year":"2012","journal-title":"J Biomed Sci"},{"issue":"2","key":"2024112123521443700_bnae020-B208","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12020-021-02612-5","article-title":"Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"2024112123521443700_bnae020-B209","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/endrev\/bnz003","article-title":"Autoimmune pituitary disease: new concepts with clinical implications","volume":"41","author":"Yamamoto","year":"2020","journal-title":"Endocr Rev"},{"issue":"1","key":"2024112123521443700_bnae020-B210","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1038\/s41598-022-08552-y","article-title":"Studies on anti-rabphilin-3A antibodies in 15 consecutive patients presenting with central diabetes insipidus at a single referral center","volume":"12","author":"Arihara","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"2024112123521443700_bnae020-B211","doi-asserted-by":"crossref","first-page":"E946","DOI":"10.1210\/jc.2014-4209","article-title":"Rabphilin-3A as a targeted autoantigen in lymphocytic infundibulo-neurohypophysitis","volume":"100","author":"Iwama","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024112123521443700_bnae020-B212","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2024112123521443700_bnae020-B213","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"1","key":"2024112123521443700_bnae020-B214","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3747\/co.26.4151","article-title":"Diabetes Mellitus secondary to treatment with immune checkpoint inhibitors","volume":"26","author":"Venetsanaki","year":"2019","journal-title":"Curr Oncol"},{"issue":"230","key":"2024112123521443700_bnae020-B215","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"2024112123521443700_bnae020-B216","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s40618-021-01627-z","article-title":"Central diabetes insipidus (infundibuloneuro hypophysitis): a late complication of COVID-19 infection","volume":"44","author":"Misgar","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2024112123521443700_bnae020-B217","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11102-021-01148-1","article-title":"COVID-19 and the pituitary","volume":"24","author":"Frara","year":"2021","journal-title":"Pituit"},{"issue":"11","key":"2024112123521443700_bnae020-B218","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3390\/cancers15112896","article-title":"History, current techniques, and future prospects of surgery to the sellar and parasellar region","volume":"15","author":"Rawanduzy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024112123521443700_bnae020-B219","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1227\/01.neu.0000318159.21731.cf","article-title":"Glioma extent of resection and its impact on patient outcome","volume":"62","author":"Sanai","year":"2008","journal-title":"Neurosurgery"},{"issue":"2","key":"2024112123521443700_bnae020-B220","first-page":"79","article-title":"The value of Pre- and intraoperative adjuncts on the extent of resection of hemispheric low-grade gliomas: a retrospective analysis","volume":"77","author":"Incekara","year":"2016","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"issue":"3","key":"2024112123521443700_bnae020-B221","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semradonc.2015.02.007","article-title":"Advances in the surgical management of low-grade glioma","volume":"25","author":"Hollon","year":"2015","journal-title":"Semin Radiat Oncol"},{"issue":"9","key":"2024112123521443700_bnae020-B222","first-page":"1869","article-title":"A systematic review of ongoing clinical trials in optic pathway gliomas","volume":"36","author":"Hill","year":"2020","journal-title":"Child Care Health Dev"},{"issue":"2","key":"2024112123521443700_bnae020-B223","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3171\/2019.2.PEDS18529","article-title":"Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic\/pilomyxoid optic pathway gliomas","volume":"24","author":"Hidalgo","year":"2019","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"2024112123521443700_bnae020-B224","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2013.8.PEDS12546","article-title":"The role of surgery in optic pathway\/hypothalamic gliomas in children","volume":"13","author":"Goodden","year":"2014","journal-title":"J Neurosurg Pediatr"},{"issue":"29","key":"2024112123521443700_bnae020-B225","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"2024112123521443700_bnae020-B226","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.2005.04.6078","article-title":"Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial","volume":"24","author":"Van Den Bent","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024112123521443700_bnae020-B227","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024112123521443700_bnae020-B228","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"issue":"10","key":"2024112123521443700_bnae020-B229","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"7854","key":"2024112123521443700_bnae020-B230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"29","key":"2024112123521443700_bnae020-B231","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1\u2014mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"2024112123521443700_bnae020-B232","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-21-0611","article-title":"Vorasidenib, a dual inhibitor of mutant IDH1\/2, in recurrent or progressive glioma; results of a first-in-human phase I trial","volume":"27","author":"Mellinghoff","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024112123521443700_bnae020-B233","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/neuonc\/noac139","article-title":"Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib\/II trial","volume":"25","author":"de la Fuente","year":"2023","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024112123521443700_bnae020-B234","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers14041003","article-title":"PARP inhibitors in glioma: a review of therapeutic opportunities","volume":"14","author":"Sim","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024112123521443700_bnae020-B235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22020587","article-title":"Updated insights on EGFR signaling pathways in glioma","volume":"22","author":"Oprita","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2024112123521443700_bnae020-B236","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.3390\/curroncol30090619","article-title":"Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update","volume":"30","author":"Alsajjan","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B237","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","article-title":"A phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme","volume":"113","author":"Li","year":"2010","journal-title":"J Neurosurg"},{"issue":"7","key":"2024112123521443700_bnae020-B238","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024112123521443700_bnae020-B239","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000533703","article-title":"A molecular update and review of current trials in paediatric low-grade gliomas","volume":"58","author":"Al-Jilaihawi","year":"2023","journal-title":"Pediatr Neurosurg"},{"issue":"15","key":"2024112123521443700_bnae020-B240","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024112123521443700_bnae020-B241","doi-asserted-by":"crossref","first-page":"e431450","DOI":"10.1200\/EDBK_431450","article-title":"State of the art in low-grade glioma management: insights from isocitrate dehydrogenase and beyond","volume":"44","author":"Schaff","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"2024112123521443700_bnae020-B242","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nox122","article-title":"Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial","volume":"19","author":"Calaminus","year":"2017","journal-title":"Neuro Oncol"},{"key":"2024112123521443700_bnae020-B243","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.wneu.2018.01.028","article-title":"Results of biopsy-proven sellar germ cell tumors: nine years\u2019 experience in a single center","volume":"112","author":"Zhang","year":"2018","journal-title":"World Neurosurg"},{"issue":"6","key":"2024112123521443700_bnae020-B244","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/WCO.0b013e32833ff522","article-title":"Update on current standard treatments in central nervous system germ cell tumors","volume":"23","author":"Kamoshima","year":"2010","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2024112123521443700_bnae020-B245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0959-8049(97)10045-4","article-title":"Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes","volume":"34","author":"Sawamura","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"2024112123521443700_bnae020-B246","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/neuonc\/noab252","article-title":"EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults","volume":"24","author":"Frappaz","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2024112123521443700_bnae020-B247","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.3892\/ol.2016.4373","article-title":"Expression and mutation of c-Kit in intracranial germ cell tumors: a single-centre retrospective study of 30 cases in China","volume":"11","author":"Gao","year":"2016","journal-title":"Oncol Lett"},{"key":"2024112123521443700_bnae020-B248","doi-asserted-by":"crossref","first-page":"1122885","DOI":"10.3389\/fphar.2023.1122885","article-title":"Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024112123521443700_bnae020-B249","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.01.033","article-title":"Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation","volume":"76","author":"Zsch\u00e4bitz","year":"2017","journal-title":"Eur J Cancer"},{"issue":"FEB","key":"2024112123521443700_bnae020-B250","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2019.00030","article-title":"Molecular targeted therapy in the treatment of chordoma: a systematic review","volume":"9","author":"Meng","year":"2019","journal-title":"Front Oncol"},{"issue":"19","key":"2024112123521443700_bnae020-B251","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"2024112123521443700_bnae020-B252","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdv300","article-title":"Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF\/GETO)","volume":"26","author":"Bompas","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"2024112123521443700_bnae020-B253","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PAS.0000000000000741","article-title":"SMARCB1\/INI1 involvement in pediatric chordoma: a mutational and immunohistochemical analysis","volume":"41","author":"Antonelli","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"2024112123521443700_bnae020-B254","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.3390\/cancers15245800","article-title":"Chordoma: a comprehensive systematic review of clinical trials","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"23","key":"2024112123521443700_bnae020-B255","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.3390\/cancers13235960","article-title":"Primary skull base chondrosarcomas: a systematic review","volume":"13","author":"Palmisciano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024112123521443700_bnae020-B256","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s11060-021-03764-0","article-title":"Long-term outcomes of grade I\/II skull base chondrosarcoma: an insight into the role of surgery and upfront radiotherapy","volume":"153","author":"Hasegawa","year":"2021","journal-title":"J Neurooncol"},{"issue":"1","key":"2024112123521443700_bnae020-B257","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2015.12.016","article-title":"Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study","volume":"95","author":"Feuvret","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2024112123521443700_bnae020-B258","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2024112123521443700_bnae020-B259","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol"},{"issue":"15","key":"2024112123521443700_bnae020-B260","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024112123521443700_bnae020-B261","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.mpdhp.2022.05.004","article-title":"A review of DICER1: structure, function and contribution to disease","volume":"28","author":"Meiklejohn","year":"2022","journal-title":"Diagnostic Histopathol"},{"issue":"1","key":"2024112123521443700_bnae020-B262","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B263","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"3","key":"2024112123521443700_bnae020-B264","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-008-0099-1","article-title":"A rare case of paraganglioma of the sella with bone metastases","volume":"12","author":"Haresh","year":"2009","journal-title":"Pituitary"},{"issue":"12","key":"2024112123521443700_bnae020-B265","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/neuonc\/nos159","article-title":"Surgery for primary CNS lymphoma? Challenging a paradigm","volume":"14","author":"Weller","year":"2012","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024112123521443700_bnae020-B266","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.beha.2018.07.006","article-title":"Improving outcomes in primary CNS lymphoma","volume":"31","author":"Graham","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"2024112123521443700_bnae020-B267","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2024112123521443700_bnae020-B268","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2024112123521443700_bnae020-B269","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/sni.sni_264_17","article-title":"Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review","volume":"9","author":"Franke","year":"2018","journal-title":"Surg Neurol Int"},{"issue":"1","key":"2024112123521443700_bnae020-B270","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024112123521443700_bnae020-B271","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024112123521443700_bnae020-B272","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J Neurooncol"},{"issue":"6","key":"2024112123521443700_bnae020-B273","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/nan.12740","article-title":"GAB1 overexpression identifies hedgehog-activated anterior skull base meningiomas","volume":"47","author":"Boetto","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2024112123521443700_bnae020-B274","volume-title":"Handbook of Clinical Neurology.","author":"M\u00fcller"},{"issue":"2","key":"2024112123521443700_bnae020-B275","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2024112123521443700_bnae020-B276","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br J Cancer"},{"issue":"7264","key":"2024112123521443700_bnae020-B277","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"issue":"6","key":"2024112123521443700_bnae020-B278","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ando.2023.10.003","article-title":"First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: case report and illustrative review","volume":"84","author":"De Rosa","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"2024112123521443700_bnae020-B279","doi-asserted-by":"crossref","first-page":"e28753","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"AUG","key":"2024112123521443700_bnae020-B280","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Oncol"},{"issue":"8","key":"2024112123521443700_bnae020-B281","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"2024112123521443700_bnae020-B282","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2024112123521443700_bnae020-B283","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B284","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng.2868","article-title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","volume":"46","author":"Brastianos","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"2024112123521443700_bnae020-B285","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"2024112123521443700_bnae020-B286","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy","volume":"108","author":"Brastianos","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2024112123521443700_bnae020-B287","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful use of BRAF\/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"2024112123521443700_bnae020-B288","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF-MEK Inhibition in newly diagnosed papillary craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2024112123521443700_bnae020-B289","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/onco.13541","article-title":"Efficacy of BRAF-inhibitor therapy in BRAFV600E-mutated adult langerhans cell histiocytosis","volume":"25","author":"Hazim","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"2024112123521443700_bnae020-B290","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024112123521443700_bnae020-B291","doi-asserted-by":"crossref","first-page":"1275085","DOI":"10.3389\/fimmu.2023.1275085","article-title":"Langerhans cell histiocytosis: current advances in molecular pathogenesis","volume":"14","author":"Sconocchia","year":"2023","journal-title":"Front Immunol"},{"issue":"16_suppl","key":"2024112123521443700_bnae020-B292","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2023.41.16_suppl.7574","article-title":"A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and\/or Erdheim-Chester disease harboring BRAFV600E mutation","volume":"1","author":"Cao","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7749","key":"2024112123521443700_bnae020-B293","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"issue":"13","key":"2024112123521443700_bnae020-B294","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood.2020005867","article-title":"Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH","volume":"137","author":"Sengal","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2024112123521443700_bnae020-B295","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2024112123521443700_bnae020-B296","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-319-22855-6_30","volume-title":"Atlas of Sellar and Parasellar Lesions.","author":"Zada","year":"2016"},{"issue":"4","key":"2024112123521443700_bnae020-B297","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2024112123521443700_bnae020-B298","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/neuonc\/noz051","article-title":"Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma","volume":"21","author":"Karajannis","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024112123521443700_bnae020-B299","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/curroncol28010071","article-title":"Rationale and design of BeatNF2 trial: a clinical trial to assess the efficacy and safety of bevacizumab in patients with neurofibromatosis type 2 related vestibular schwannoma","volume":"28","author":"Fujii","year":"2021","journal-title":"Curr Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B300","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J Neurooncol"},{"issue":"2","key":"2024112123521443700_bnae020-B301","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024112123521443700_bnae020-B302","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J Neurooncol"},{"issue":"28","key":"2024112123521443700_bnae020-B303","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"S2","key":"2024112123521443700_bnae020-B304","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/epi.13751","article-title":"Laser interstitial thermal therapy: a first line treatment for seizures due to hypothalamic hamartoma?","volume":"58","author":"Du","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"2024112123521443700_bnae020-B305","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation","volume":"33","author":"Gubbi","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"2024112123521443700_bnae020-B306","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jocn.2015.01.019","article-title":"Xanthomatous hypophysitis","volume":"22","author":"Hanna","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"1","key":"2024112123521443700_bnae020-B307","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13256-019-2276-4","article-title":"Idiopathic granulomatous hypophysitis presenting with galactorrhea, headache, and nausea in a woman: a case report and review of the literature","volume":"13","author":"Sharifi","year":"2019","journal-title":"J Med Case Rep"},{"issue":"7","key":"2024112123521443700_bnae020-B308","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-20-0513","article-title":"Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns","volume":"28","author":"Nguyen","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2024112123521443700_bnae020-B309","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2024112123521443700_bnae020-B310","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2024112123521443700_bnae020-B311","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2024112123521443700_bnae020-B312","doi-asserted-by":"crossref","first-page":"bvaa048","DOI":"10.1210\/jendso\/bvaa048","article-title":"A case series of patients with isolated IgG4-related hypophysitis treated with rituximab","volume":"4","author":"Boharoon","year":"2020","journal-title":"J Endocr Soc"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnae020\/58801147\/bnae020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/45\/6\/880\/60764160\/bnae020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/45\/6\/880\/60764160\/bnae020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T23:54:10Z","timestamp":1732233250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/45\/6\/880\/7721527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":312,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,26]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnae020","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,26]]}}}